Examkin

Soru

Zorluk: ZorMonitoring and Treatment Evaluation

A 22-year-old man with type 1 diabetes mellitus is managed in the intensive care unit for diabetic ketoacidosis (DKA). He has been receiving a continuous intravenous regular insulin infusion, appropriate intravenous fluids, and potassium supplementation for the past 1414 hours. The most recent basic metabolic panel reveals a blood glucose of 185185 mg/dL, a serum bicarbonate of 1919 mEq/L, and a calculated anion gap of 1010 mEq/L. The patient is awake, alert, and states he is hungry. The physician decides to transition the patient from intravenous to subcutaneous insulin therapy. Arrange the following steps in the most appropriate chronological order to safely accomplish this therapeutic transition and ongoing monitoring.

  1. 1Document resolution of ketoacidosis and verify the patient's ability to tolerate oral intake.
  2. 2Administer the initial dose of subcutaneous basal and short-acting (prandial) insulin.
  3. 3Maintain the continuous intravenous regular insulin infusion for a 11- to 22-hour overlap period.
  4. 4Discontinue the continuous intravenous regular insulin infusion.
  5. 5Initiate routine capillary blood glucose monitoring before meals and at bedtime.

Cevap

The correct sequence for transitioning a patient from intravenous to subcutaneous insulin after DKA resolution is: 1) Document DKA resolution and oral tolerance, 2) Administer subcutaneous insulin, 3) Continue IV insulin for a 1-2 hour overlap, 4) Stop IV insulin, 5) Begin routine pre-meal and bedtime blood glucose monitoring.
The correct sequence follows guideline-directed de-escalation of DKA management. First, criteria for resolution must be met (glucose < 200200 mg/dL, bicarbonate \geq 1818 mEq/L, and calculated anion gap \leq 1212 mEq/L) and the patient must tolerate oral intake. Next, subcutaneous insulin (both basal and prandial) is administered. Crucially, the intravenous regular insulin infusion must be continued for 11 to 22 hours after the subcutaneous injection. This overlap is required because intravenous insulin has a half-life of less than 1010 minutes, whereas subcutaneous insulin takes 11 to 22 hours to achieve significant systemic absorption. Stopping the IV infusion prematurely leads to a lapse in circulating insulin and rebound ketoacidosis. Once the overlap period concludes, the IV infusion is stopped, and the patient is placed on routine blood glucose monitoring to evaluate the new regimen.

Adım Adım Çözüm

1
Confirm clinical and biochemical resolution
Anion gap is closed (\leq 1212 mEq/L) and patient can eat.
Ensures the patient is physiologically ready for therapeutic de-escalation.
2
Administer subcutaneous insulin
Patient receives basal and prandial SQ dose.
Provides the new source of insulin before the old one is removed.
3
Overlap IV and SQ insulin
IV infusion runs concurrently for 11-22 hours post-SQ injection.
Prevents insulin deficiency and rebound DKA while SQ insulin absorbs.
4
Stop IV insulin
Patient is solely on SQ insulin.
Completes the transition once SQ insulin is fully active.
5
Start routine monitoring
Point-of-care glucose checks are scheduled before meals and at bedtime.
Allows evaluation of the new SQ regimen's efficacy and ensures stability.

Anahtar Kavram

Multi-step therapeutic de-escalation and monitoring protocol for Diabetic Ketoacidosis (DKA)
Bu soruyu puanla

Konular

Monitoring and Treatment Evaluation

Bu konudan daha fazla soru